Biosimilar Market Formation Isn't Going According To Plan
This article was originally published in The Pink Sheet Daily
Executive Summary
As user fee negotiations begin, FDA has far more sponsors in product development phase and far fewer marketing applications than anticipated.
You may also be interested in...
PDUFA Fees Forced Down For FY 2017 Due To Refund Provision
Final year of this user fee cycle will include 14% discount, but agency says it is ready for revenue reduction.
PDUFA Fees Forced Down For FY 2017 Due To Refund Provision
Final year of this user fee cycle will include 14% discount, but agency says it is ready for revenue reduction.
Biosimilar User Fee Negotiations Won't Start Until 2016
Mid-December kick-off meeting puts emerging user fee program on much later track than others.